We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 10, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Thermo Fisher Scientific Inc. (TMO - Free Report) , Starbucks Corp. (SBUX - Free Report) , Moderna, Inc. (MRNA - Free Report) , Canadian Pacific Railway Ltd. (CP - Free Report) and Micron Technology, Inc. (MU - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Thermo-Fisher, Starbucks and Moderna
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc., Starbucks Corp. and Moderna, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Thermo Fisher Scientific have held up relatively better compared to the broader market on the back of favorable momentum in parts of its business, particularly the Analytical Instruments, Laboratory Products and Biopharma Services segments. The stock lost -11.9% of its value over the past year, which compares to the Zacks Medical sector's -14% decline and the S&P 500 index's -18% pullback.
Thermo Fisher’s accelerated investments to expand bioproduction capacity also buoy optimism. In the quarter, the company has witnessed strength in three out of its four end markets. The upbeat guidance for 2022 is indicative that this growth momentum will continue.
Starbucks shares have outperformed the Zacks Retail - Restaurants industry over the past year (+0.6% vs. -2.2%). Operating fundamentals such as a solid global footprint, successful innovations and digital offerings have aided the company.
North America comps continue to impress investors. For fiscal 2023, the company anticipates global comparable sales to reach the high end of 7-9% target range.
However, its performance continues to be negatively impacted by dismal China results, higher-than-expected inflationary pressures, increased costs and a tight labor market.
Shares of Moderna have underperformed the Zacks Medical - Biomedical and Genetics industry over the past year (-22.8% vs. +16.6%). The company is witnessing decline in product sales due to lower cases of COVID-19 infections which results in uncertainty regarding demand for vaccinations. The launch of COVID vaccines by competitors like Sanofi and Novavax will also likely lead to loss of product sales.
Being one of the first-ever COVID vaccine developers, the robust product sales boosted cash resources. This has helped Moderna to progress with its other pipeline candidates, whose development is promising. Currently, Moderna is conducting three ongoing late-stage studies evaluating RSV, CMV and influenza vaccines. However, these candidates are still years away from commercialization.
Other noteworthy reports we are featuring today include Canadian Pacific Railway Ltd. and Micron Technology, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology
For Immediate Release
Chicago, IL – January 10, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Thermo Fisher Scientific Inc. (TMO - Free Report) , Starbucks Corp. (SBUX - Free Report) , Moderna, Inc. (MRNA - Free Report) , Canadian Pacific Railway Ltd. (CP - Free Report) and Micron Technology, Inc. (MU - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Thermo-Fisher, Starbucks and Moderna
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc., Starbucks Corp. and Moderna, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Thermo Fisher Scientific have held up relatively better compared to the broader market on the back of favorable momentum in parts of its business, particularly the Analytical Instruments, Laboratory Products and Biopharma Services segments. The stock lost -11.9% of its value over the past year, which compares to the Zacks Medical sector's -14% decline and the S&P 500 index's -18% pullback.
Thermo Fisher’s accelerated investments to expand bioproduction capacity also buoy optimism. In the quarter, the company has witnessed strength in three out of its four end markets. The upbeat guidance for 2022 is indicative that this growth momentum will continue.
(You can read the full research report on Thermo Fisher Scientific here >>>)
Starbucks shares have outperformed the Zacks Retail - Restaurants industry over the past year (+0.6% vs. -2.2%). Operating fundamentals such as a solid global footprint, successful innovations and digital offerings have aided the company.
North America comps continue to impress investors. For fiscal 2023, the company anticipates global comparable sales to reach the high end of 7-9% target range.
However, its performance continues to be negatively impacted by dismal China results, higher-than-expected inflationary pressures, increased costs and a tight labor market.
(You can read the full research report on Starbucks here >>>)
Shares of Moderna have underperformed the Zacks Medical - Biomedical and Genetics industry over the past year (-22.8% vs. +16.6%). The company is witnessing decline in product sales due to lower cases of COVID-19 infections which results in uncertainty regarding demand for vaccinations. The launch of COVID vaccines by competitors like Sanofi and Novavax will also likely lead to loss of product sales.
Being one of the first-ever COVID vaccine developers, the robust product sales boosted cash resources. This has helped Moderna to progress with its other pipeline candidates, whose development is promising. Currently, Moderna is conducting three ongoing late-stage studies evaluating RSV, CMV and influenza vaccines. However, these candidates are still years away from commercialization.
(You can read the full research report on Moderna here >>>)
Other noteworthy reports we are featuring today include Canadian Pacific Railway Ltd. and Micron Technology, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.